Only a few CAR candidates have been studied in humans with GBM, since the target of CAR T cells should not be expressed on healthy cells to avoid an autoimmune response against the brain.83 Brown et al84 conducted a phase I trial with IL-13 Ra2 CAR T (NCT02208362) and reported a case of transient complete response (PFS 7.5 months) in a patient with recurrent multifocal GBM reporting a marked improvement in terms of quality of life. The gene discussed is IL13; the disease is glioblastoma.